免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展  

Application Progress of Immune Checkpoint Inhibitors in Oncogene-driven Advanced Non-small Cell Lung Cancer

作　　者：张同梅(综述)[1] 李宝兰(审校)[1] Tongmei ZHANG;Baolan LI(Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing 101149,China)

机构地区：[1]首都医科大学附属北京胸科医院综合科,北京市结核病胸部肿瘤研究所,北京101149

出　　处：《中国肺癌杂志》2021年第3期188-195,共8页Chinese Journal of Lung Cancer

基　　金：北京科学技术委员会项目(No.Z171100001017038);通州区科学技术委员会项目(No.KJ2020CX010);通州区运河人才项目(No.YHLD2018026)资助。

摘　　要：随着肿瘤精准医学的发展,驱动基因阳性非小细胞肺癌(non-small cell lung cancer,NSCLC)患者接受靶向治疗极大地改善了生存和预后,但不管是哪代靶向药物均不可避免的会经历耐药,患者会面临无靶可用的局面。免疫检查点抑制剂因其特有的长拖尾效应,能给部分晚期NSCLC患者带来长生存。越来越多的研究显示免疫治疗同样可为部分驱动基因阳性NSCLC患者带来获益,但免疫治疗介入的时机、治疗方案的选择以及预测生物标记物等问题仍不十分明确,值得进一步探讨。With the development of precise medicine,targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer(NSCLC)with oncogenic drivers.However,no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance,treatment options upon exhaustion of targeted therapies are limited.Immune checkpoint inhibitors(ICIs)can bring long-term survival to some patients with advanced NSCLC because of its unique long tailing effect.More and more studies have shown that ICIs can also benefit NSCLC patients with oncogenic drivers.However,the timing of ICIs intervention,the therapeutic regimen and the predictive biomarkers are actually debated,underscoring the need to explore the potential interest of ICIs in these populations.

关 键 词：肺肿瘤 驱动基因 免疫检查点抑制剂 预测 

分 类 号：R734.2[医药卫生—肿瘤]